Mark Hilliard’s Post

View profile for Mark Hilliard, graphic

Principal Scientist, MSAT, Pfizer. 🧬🔬⚗️🧫💊 ⌬

Some interesting work by Sun et al on the development of mass spectrometry bases assay for the development of single base modifactions (N6-methyladenosine (m6A) and N6, 2′-odimethyladenosine (m6Am). 🛎Overview: Sun et al firstly chemical degenerated samples into 100-150 nucleotides lengths, secondly this was followed by RNA enriched with m6A-specific antibodies. Subsequently, complementary DNA probes were designed to specifically target and enrich candidate RNA fragments with m6A and m6Am modifications. The RNA-probe hybrids were then treated with RNase A/T1 mix, leading to the degradation of non-hybridized RNAs and the targets of interest are preserved. This is the analysed by nano LCMS . 🎯Summery: Sun et al validated their assay against MeRIP-qPCR assay, Sun et al observed significant enrichment.  Furthermore sun et al successfully applied to the detection of m6A or m6Am sites of target RNA fragments in cell and tissue samples. 📑 Publication link: https://lnkd.in/en9d7JYk #pharma #biotherapeutics #biopharma #chemistry #science #scienceandtechnology #processdevelopment #pregnancy #processmonitoring #massspectrometry #massspec #biopharmaceuticals #bioanalytical #biotech #science #scienceandtechnology #research #chemistry #mrna #bioprocessing #chromatography #nucleotides #rnatherapeutics #oligonucleotides #biotech #LCMS

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics